The DOI matches its Crossref record; 443 of the 443 references it cites were found in a registry or an index.
The hallmarks of cancer immune evasion
Open accessAbstract
According to the widely accepted "three Es" model, the host immune system eliminates malignant cell precursors and contains microscopic neoplasms in a dynamic equilibrium, preventing cancer outgrowth until neoplastic cells acquire genetic or epigenetic alterations that enable immune escape. This immunoevasive phenotype originates from various mechanisms that can be classified under a novel "three Cs" conceptual framework: (1) camouflage, which hides cancer cells from immune recognition, (2) coercion, which directly or indirectly interferes with immune effector cells, and (3) cytoprotection, which shields malignant cells from immune cytotoxicity. Blocking the ability of neoplastic cells to evade the host immune system is crucial for increasing the efficacy of modern immunotherapy and conventional therapeutic strategies that ultimately activate anticancer immunosurveillance. Here, we review key hallmarks of cancer immune evasion under the "three Cs" framework and discuss promising strategies targeting such immunoevasive mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 401–443 of 443
Ritter, C., Fan, K., Paulson, K. G., Nghiem, P., Schrama, D., & Becker, J. C. (2016) · Scientific Reports · doi:10.1038/srep21678 · Cited by 61
Chen, X., Liu, X., Ding, X., Zhang, J., Jiang, L., Liu, S., Hou, H., Jiang, B., Cheng, L., Zhu, Q., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.828319 · Cited by 59
Cichocki, F. M., Zhang, B., Wu, C.-Y., Chiu, E., Day, A., O’Connor, R. S., Yackoubov, D., Simantov, R., McKenna, D. H., Cao, Q., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.ade3341 · Cited by 59
Truxova, I., Kasikova, L., Salek, C., Hensler, M., Lysak, D., Holicek, P., Bilkova, P., Holubova, M., Chen, X., Mikyskova, R., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.223933 · Cited by 56
Self-citationA TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency
Naour, J. L., Liu, P., Zhao, L., Adjemian, S., Sztupinszki, Z. M., Taïeb, J., Mulot, C., Silvin, A., Dutertre, C., Ginhoux, F., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0465 · Cited by 56
King, C. R., Liu, Y., Amato, K. A., Schaack, G. A., Mickelson, C. K., Sanders, A. E., Hu, T., Gupta, S., Langlois, R. A., Smith, J. A., et al. (2023) · Cell Host & Microbe · doi:10.1016/j.chom.2023.08.001 · Cited by 56
Zhang, Y., Xiang, C., Wang, Y., Duan, Y., Liu, C., & Zhang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.21328 · Cited by 55
Vringer, E., Heilig, R., Riley, J. S., Black, A. R. S., Cloix, C., Skalka, G., Montes-Gómez, A. E., Aguado, A., Lilla, S., Walczak, H., et al. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00044-1 · Cited by 55
Zhang, B., Wang, C., Wu, H., Wang, F., Chai, Y., Hu, Y., Wang, B., Zhou, Y. L., Xia, R., Xu, R., et al. (2023) · 癌症:英文版 · doi:10.1002/cac2.12476 · Cited by 51
Iadonato, S. P., Ovechkina, Y. Y., Lustig, K., Cross, J., Eyde, N., Frazier, E., Kabi, N., Katz, C., Lance, R., Peckham, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1311658 · Cited by 51
Faletti, S., Osti, D., Ceccacci, E., Richichi, C., Costanza, B., Nicosia, L., Noberini, R., Marotta, G., Furia, L., Faretta, M., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abf7036 · Cited by 49
Zhou, Y., Wang, D., Zhou, L., Zhou, N., Wang, Z., Chen, J., Pang, R., Fu, H., Huang, Q., Dong, F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45750-w · Cited by 48
Jiang, C., Sun, H., Jiang, Z., Tian, W., Cang, S., & Yu, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1378647 · Cited by 48
Contribution of annexin A1 to anticancer immunosurveillance
Baracco, E. E., Stoll, G., Endert, P. V., Zitvogel, L., Vacchelli, E., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1647760 · Cited by 47
Chen, L., Shi, V., Wang, S., Sun, L., Freeman, R., Yang, J., Inkman, M. J., Ghosh, S., Ruiz, F., Jayachandran, K., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163841 · Cited by 45
Non-mutational neoantigens in disease
Stern, L. J., Clement, C. C., Galluzzi, L., & Santambrogio, L. (2024) · Nature Immunology · doi:10.1038/s41590-023-01664-1 · Cited by 43
Self-citationKim, I., Diamond, M. S., Yuan, S., Kemp, S. B., Kahn, B., Li, Q., Lin, J. H., Li, J., Norgard, R. J., Thomas, S. K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46048-7 · Cited by 42
Ye, S.-Y., Li, J.-Y., Li, T., Song, Y., Sun, J., Chen, X., Zhao, J., Li, Y., Wu, Z., Gao, P., et al. (2022) · Current Oncology · doi:10.3390/curroncol29090482 · Cited by 39
Epigenetic modification of CSDE1 locus dictates immune recognition of nascent tumorigenic cells
Lv, J., Zhou, Y., Zhou, N., Wang, Z., Chen, J., Chen, H., Wang, D., Zhou, L., Wei, K., Zhang, H., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abq6024 · Cited by 39
Zhao, X., Hu, S., Zeng, L., Liu, X., Song, Y., Zhang, Y., Chen, Q., Bai, Y., Zhang, J., Zhang, H., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104690 · Cited by 37
Radiotherapy transiently reduces the sensitivity of cancer cells to lymphocyte cytotoxicity
Tuomela, K., Mukherjee, D., Ambrose, A. R., Harikrishnan, A., Mole, H., Hurlstone, A. F. L., Önfelt, B., Honeychurch, J., & Davis, D. M. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2111900119 · Cited by 35
Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons
Liu, Y., Hu, L., Wu, Z., Yuan, K., Hong, G., Lian, Z., Feng, J., Li, N., Li, D., Wong, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39943-y · Cited by 35
Selvanesan, B. C., Meena, K., Beck, A. P., Meheus, L., Lara, O., Rooman, I., & Gravekamp, C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001250 · Cited by 33
Naka, K., Ishihara, K., Jomen, Y., Jin, C. H., Kim, D., Gu, Y., Jeong, E., Li, S., Krause, D. S., Kim, D., et al. (2015) · Cancer Science · doi:10.1111/cas.12849 · Cited by 32
Apoptotic contraction drives target cell release by cytotoxic T cells
Sanchez, E. E., Tello‐Lafoz, M., Guo, A. J., de Jesus, M., Elbanna, Y. A., Winer, B. Y., Budhu, S., Chan, E., Rosiek, E., Kondo, T., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01572-4 · Cited by 32
Beck, L. D., Melhaoui, S., Veirman, K. D., Menu, E., Bruyne, E. D., Vanderkerken, K., Breckpot, K., & Maes, K. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1484981 · Cited by 31
Mahalingam, D., Harb, W. A., Patnaik, A., Bullock, A. J., Watnick, R. S., Vincent, M. Y., Chen, J., Wang, S., Pestana, H. R., Chao, J., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00433-x · Cited by 31
Thomas, A. A., Fisher, J. L., Hampton, T. H., Christensen, B. C., Tsongalis, G. J., Rahme, G. J., Whipple, C. A., Steel, S. E., Davis, M. C., Gaur, A. B., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1941-3 · Cited by 28
Apoptotic caspases cut down the immunogenicity of radiation
Buqué, A., Rodriguez-Ruiz, M. E., Fucikova, J., & Galluzzi, L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655364 · Cited by 28
Self-citationHuang, R. S. P., Murugesan, K., Montesion, M., Pavlick, D. C., Mata, D. A., Hiemenz, M., Decker, B. J., Frampton, G. M., Albacker, L. A., & Ross, J. S. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002680 · Cited by 28
Hong, J., Lee, J. H., Zhang, Z., Wu, Y., Yang, M., Liao, Y., de la Rosa, R., Scheirer, J. L., Pechacek, D., Zhang, N., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0736 · Cited by 28
Singh, S., & Banerjee, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-62081-0 · Cited by 25
Klaihmon, P., Luanpitpong, S., Kang, X., & Issaragrisil, S. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03153-9 · Cited by 25
Jovanovic, M. Z., Geller, D., Gajović, N., Jurišević, M., Arsenijević, N., Jovanović, M. M., Šupić, G., Vojvodic, D., & Jovanovic, I. (2021) · Life Science · doi:10.1016/j.lfs.2021.120214 · Cited by 24
Wylie, B., Chee, J., Forbes, C. A., Booth, M. W., Stone, S. R., Buzzai, A. C., Abad, A., Foley, B. A., Cruickshank, M. N., & Waithman, J. C. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1609874 · Cited by 20
Vugmeyster, Y., Wilkins, J. J., Köenig, A., Bawab, S. E., Dussault, I., Ojalvo, L. S., Banerjee, S. D., Klopp‐Schulze, L., & Khandelwal, A. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1776 · Cited by 20
Geng, Q., & Jiao, P. (2024) · Molecules · doi:10.3390/molecules29020454 · Cited by 19
Berlin, J. D., Harb, W. A., Adjei, A. A., Xing, Y., Swiecicki, P. L., Seetharam, M., Nandagopal, L., Gopal, A. K., Xu, C., Xu, C., et al. (2020) · Regular and Young Investigator Award Abstracts · doi:10.1136/jitc-2020-sitc2020.0385 · Cited by 16
Combination of IL-33 with PD-1 blockade augment mILC2s-mediated anti-tumor immunity
Yue, J., Guo, H. M., Xu, P., Ma, J., Shi, W., & Wu, Y. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03580-7 · Cited by 16
Hoffman-Censits, J. H., Grivas, P. D., Powles, T. B., Hawley, J. E., Tyroller, K., Seeberger, S., Guenther, S., Jacob, N., Mehr, K. T., & Hahn, N. M. (2023) · Future Oncology · doi:10.2217/fon-2023-0492 · Cited by 15
Lin, G. H. Y., Viller, N. N., Chabonneau, M., Brinen, L., Mutukura, T., Dodge, K., Helke, S., Chai, V., House, V., Lee, V., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-2709 · Cited by 14
Santasusagna, S., Zhu, S.-J., Jawalagatti, V., Carceles-Cordon, M., Ertel, A., García-Longarte, S., Song, W.-M., Fujiwara, N., Li, P.-Y., Mendizabal, I., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0306 · Cited by 13
Diong, S., Jashnani, A., Drake, A. W., Bee, C., Findeisen, F., Dollinger, G. D., Wang, F., Rajpal, A., Strop, P., & Lee, P. S. (2023) · mAbs · doi:10.1080/19420862.2023.2253788 · Cited by 12
Research works printed but not linked: 4
- Clement, 2021, 3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine, Nat. Commun., 12, 4447, 10.1038/s41467-021-24785-3 · doi:10.1038/s41467-021-24785-3
- Sun, 2024, A phase I/II, open-label, multicenter study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of HB0036 in patients with advanced solid tumors, J. Clin. Oncol., 42, e14504, 10.1200/JCO.2024.42.16_suppl.e14504 · doi:10.1200/jco.2024.42.16_suppl.e14504
- Claff, 2023, Crystal structure of adenosine A(2A) receptor in complex with clinical candidate Etrumadenant reveals unprecedented antagonist interaction, Commun. Chem., 6, 106, 10.1038/s42004-023-00894-6 · doi:10.1038/s42004-023-00894-6
- Park, 2022, A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer, BMC Cancer, 22, 28, 10.1186/s12885-021-09138-z · doi:10.1186/s12885-021-09138-z
Cited by
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Gouez, M., Pérol, O., Pialoux, V., Avrillon, V., Boussageon, M., Decroisette, C., Delrieu, L., El Hajj, H., Fournier, B., Gille, R., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15010334 · Cited by 3
“ICPi efficacy depends on effective antitumor immune response, including adequate immune system competence, tumor infiltration by T lymphocytes, recognition of tumor-specific antigens, and a permissive tumor microenvironment [6,7].”
Metadata
- Authors
- Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2024-11
- Volume
- 42
- Issue
- 11
- Pages
- 1825-1863
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W4403299725
- Cited by
- 565
- References
- 443
- FWCI
- 86.56
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 375 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Funders
- American-Italian Cancer Foundation (223565-01)
- National Cancer Institute (CA271915)
- Leukemia and Lymphoma Society
- Associazione Italiana per la Ricerca sul Cancro (IG 2022 27685)
- National Institutes of Health
- Stand Up To Cancer
- Weill Cornell Medicine
- Luke Heller Tec Pr2 Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.